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A B S T R A C T
Lithium, besides mood stabilization, might be involved in neuroprotection. Previously we have found that the treat-
ment with lithium increased the levels of p21WAF/Cip1 and survivin in human glioblastoma A1235 cells. The aim of the
present study was to examine the cytotoxic effect of glutamate on these cells, and to determine whether lithium can protect
A1235 cells against toxic effects of glutamate. Cytotoxicity of glutamate was examined by spectrophotometric MTT assay,
while the expression of apoptosis related genes was examined by Western blot method. Glutamate was excessively cyto-
toxic for A1235 cells only in concentrations higher than 100 mM. It did not induce apoptosis, but rather suppressed
survivin expression and increased the level of p21WAF/Cip1. Pretreatment with lithium (2 mM) partially reverted change in
survivin expression induced by glutamate, suggesting that lithium may have beneficial effect on glutamate induced cell
damage in glioblastoma cells.
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Introduction
Lithium has been used as an effective mood-stabiliz-
ing drug for the treatment of manic episodes and depres-
sion for 50 years1,2. However, both, the biochemical me-
chanisms underlying the pathogenesis of these disorders
and the mechanisms by which lithium exerts its thera-
peutic effects are not yet completely understood. Experi-
ments support multiple targets of lithium regulating the
expression of numerous molecules and enzymes2,3. Re-
cently, lithium has been found to protect neurons from
the death induced by a wide array of neurotoxic insults
such as glutamate, low extracellular potassium levels,
oubain, valinomycin, aluminum, phenytoin, carbamaze-
pine, C2-ceramide etc 2,4–13. This effect was partially
based on the altered level of apoptosis related genes8,9,12,13.
Not only that lithium suppressed the induction of apop-
tosis, but it also exerted neurotrophic effects2,14,15.
Glutamate is an excitatory neurotransmitter in the
central nervous system, that operates as a modulator of
synaptic transmission16. Activation of glutamate recep-
tors can trigger cell death of neurons and some types of
glial cells, particularly when the cells are coincidentally
subjected to adverse conditions such as reduced levels of
oxygen or glucose, increased levels of oxidative stress, ex-
posure to toxic or other pathogenic agents, or a dis-
ease-causing genetic mutations. Excitotoxic cell death in-
volves excessive calcium influx and release from internal
organelles, oxyradical production, and engagement of
programmed cell death cascade. It has been implicated in
neuronal death in a variety of neuropsychiatric disea-
ses16,17.
In our previous study we have shown that the treat-
ment with lithium increased the levels of p21WAF/Cip1 and
survivin in human glioblastoma cells18, suggesting that
increased expression of p21WAF/Cip (a protein with anti-
apoptotic function), and survivin (a protein that supports
the growth of cells by suppression of apoptosis and pro-
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motion of cell proliferation), can be the early events in
the long-term cell response to lithium, that may be in-
volved in the beneficial effects of this drug. The aim of
the present study was to examine the cytotoxic effect of
glutamate in glioblastoma cells, and to determine whe-




In this study, we used human glioblastoma cells A1235.
They were grown in plastic Petri dishes as a monolayer
culture in Dulbecco’s medium (DMEM) (GIBCO BRL)
with 10% fetal bovine serum (FBS) (GIBCO BRL) and
antibiotics (50 g/mL streptomycin and 100 IU/mL peni-
cillin) at 37 °C with 5% CO2.
Lithium and glutamate
Lithium chloride and glutamate (Sigma, Steinheim,
Germany) were dissolved in water at concentration of 20
M (lithium) or 6 M (glutamate). These stock solutions
were sterilized by filtration (Millipore Corporation, Bed-
ford, MA, 01730, USA) and stored at –20 °C. They were
diluted with the growth medium immediately before use
(glutamate in the final concentrations 10–200 mM, and
lithium in the therapeutic doses 0.5 mM and 2 mM).
Cytotoxicity assay
The sensitivity of human glioblastoma cells to gluta-
mate was determined using a colorimetric MTT assay19,
modified as described20. Briefly, 4.5×103 cells were seed-
ed in 0.18 mL of medium per well in 96-well microtitre
tissue culture plates. On the following day, different con-
centrations of glutamate were added (0.02 mL) to each
well; each concentration was tested in quadruplicate.
The cells were continuously treated for 72 h at 37 °C.
Thereafter, the medium was aspirated and 20 mg/mL of
MTT dye/0.04 mL medium was added to each well. Fol-
lowing 4 h of incubation at 37 °C, formazan crystals were
dissolved in dimethyl sulfoxide (0.17 mL/well). The pla-
tes were mechanically agitated for 5 min and optical den-
sity at 540 nm was determined on a microtiter plate
reader. If the influence of lithium pretreatment was stud-
ied, the cells were seeded as described above, the next
day lithium was added (0.5 or 2 mM) and incubated for
48 h. Thereafter glutamate was added (80 –180 mM) and
incubated for the next 24 h. The cytotoxicity was deter-
mined as described above. Each experiment was repeated
three times.
Western blot analysis
Protein extracts of cells were prepared by lysing cells
in RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% sodium
deoxycholate, 0.1% SDS, 50 mM Tris HCl, pH 8) with 10
mM EDTA and 1 mM PMSF for 30 min at 4 °C. The sam-
ples were then centrifuged for 15 min at 15 000 g. Pro-
tein concentration in supernatant was determined ac-
cording to the Lowry method21. For each sample, 60 mg of
protein were loaded on 12.5% SDS-polyacrylamide gel,
electrophoresed, and transferred to nitrocellulose mem-
brane (0.22 mm, Protran, Schleicher & Schuell). The
membrane was blocked for 1 hour at room temperature
with the blocking buffer (TBS containing 0.1% Tween 20
(w/v) (Sigma) and 5% milk (w/v) (Sirela, Croatia)). Pri-
mary antibodies (applied for 1 hour at room tempera-
ture, or overnight at 4 °C) were: anti-PARP (mouse
monoclonal C2-10, Pharmingen, USA), anti-caspase-3
(mouse monoclonal E-8, Santa Cruz), anti p21WAF/Cip1
(WAF1) (mouse monoclonal Ab-1, Oncogene), anti-survi-
vin (rabbit polyclonal FL-142, Santa Cruz) and anti-ERK2
(rabbit polyclonal C-14, Santa Cruz). Anti-caspase-3 and
anti-survivin were diluted 1:1000, anti-PARP 1:4000,
anti-ERK2 1:3000, and anti-p21 1:300. Thereafter, mem-
branes were incubated for 1 h with HRP-labeled second-
ary antibodies (Amersham Pharmacia Biotech, Sweden):
sheep anti-mouse NA 931 (diluted 1:2500), and donkey
anti-rabbit NA 934 (diluted 1:5000), and then developed
by an ECL system according to manufacturer’s instruc-
tions (Amersham). The experiments were repeated three
times.
Results
Cytotoxic effect of glutamate on human glioblastoma
cells is shown in Figure 1. Reduction in cell survival was
detected for the doses higher than 30 mM, but for a high
decrease in cell survival elevated doses (over 100 mM) of
glutamate were needed. According to the survival curve,
for the investigation of cell death following doses were
selected: 80, 100, 150 and 180 mM. As shown in Figure 2,
24 h the treatment with glutamate did not induce the
cleavage of PARP, or reduced the level of procaspase 3
(the hallmarks of apoptosis), but it reduced the level of
survivin. Following the 72 h treatment, again, no cleav-
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Fig. 1. Cytotoxic effect of 72 h treatment with glutamate (Glut) on
survival of human glioblastoma A1235 cells assayed by a modi-
fied MTT method. Result in each point represents mean values
from 3 experiments (X± SD).
age of PARP, or alteration in the level of procaspase 3 was
detected. While the level of survivin was similar to the
one found in the control, the expression of p21WAF/Cip sig-
nificantly increased (Figure 3).
The pretreatment with lithium (0.5 and 2.0 mM) did
not alter the survival of cells treated with glutamate (the
data obtained with 2 mM lithium are depicted on Figure
4). The analysis of apoptosis related proteins showed no
cleavage of PARP, or alteration in the level of procaspase
3, but partially reverted levels of survivin expression in-
duced by glutamate if the cells were pretreated with 2
mM dose of lithium (Figure 5).
Discussion
Lithium has been used clinically for more than 50
years as a mood-stabilizing drug in the treatment of bipo-
lar disorders and other mood disorders1,2. Neuropro-
tective effects of this drug have been evidenced by pre-
clinical and clinical studies as well2,4–13.. Glutamate is an
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Fig. 2. Western blot analysis of PARP, procaspase-3, survivin and
p21WAF/Cip1 protein expression in human glioblastoma A1235 cells
after 24 h treatment with 80, 100, 150 and 180 mM of glutamate.
C24 are control cells. ERK-2 was used as equal loading control.
HeLa cells treated with cisplatin (CDDP) or doxorubicin (DOX)
were used as positive controls for PARP and caspase cleavage.
(CDDP: cells were treated for 1 h with 80 M cisplatin and col-
lected 24 h after the treatment; DOX: cells were treated for 24 h
with 2.6 M DOX and collected 24 h later). Shown are represen-
tative blots.
Fig. 3. Western blot analysis of PARP, procaspase-3, survivin and
Magnetic Resonance after 72 h treatment with 80, 100, 150 and
180 mM of glutamate. C72 are control cells. ERK-2 was used as
the control for equal loading. HeLa cells treated with cisplatin
(CDDP) or doxorubicin (DOX) were used as positive controls for
PARP and caspase cleavage. (CDDP: cells were treated for 1 h
with 80 mM cisplatin and collected 24 h after the treatment; DOX:
cells were treated for 24 h with 2.6 mM DOX and collected 24 h
later). Shown are representative blots.
Fig. 4. Survival curves of glioblastoma A1235 cells following 24 h
incubation with glutamate (Glut) with or without 48 h pretreat-
ment with 2 mM lithium (LiCl). Pooled data from three experi-
ments (X±SD).
Fig. 5. Western blot analysis of PARP, procaspase-3, survivin and
p21WAF/Cip1 protein expression in human glioblastoma A1235 cells
following: 24 h treatment with glutamate (Glut, 180 mM), 48 h
treatment with 0.5 mM lithium (0.5), 48 h treatment with 2 mM
lithium (2), 48 h treatment with 0.5 mM lithium and then incu-
bation for 24 h with 180 mM glutamate (0.5 + G), 48 h treatment
with 2 mM lithium and then incubation for 24 h with 180 mM
glutamate (2 + G). C72 are control cells. Shown are representa-
tive blots.
excitatory neurotransmitter in the central nervous sys-
tem, that may cause cell death16. The aim of the present
study was to evaluate possible neuroprotective effect of
lithium on glutamate induced damage in human glio-
blastoma A1235 cells.
As evident from Figure 4, glioblastoma cells are resis-
tant to high doses of glutamate. The possible explanation
of this resistance could be that glioma cells from patients
or established cell cultures release large amounts of
glutamate22. These cells may be protected from gluta-
mate excitotoxic effect by impaired glutamate uptake22,
or by specific genetic alterations that reduce their ability
to undergo cell death. In the latter case high intracellular
content of antioxidant gluthatione could prevent gluta-
mate induced oxidative stress23. As shown in the present
study, glutamate applied in high doses did not induce the
cleavage of PARP, or reduced the level of procaspase 3
(the hallmarks of apoptosis) (Figures 2 and 3). The ab-
sence of apoptosis could be based on the observation that
glutamate can induce different types of cell death vary-
ing from apoptosis, over apoptosis-like cell death to ne-
crosis, suggesting the involvement of cell-type and cellu-
lar context specificity in this process24–26. This is not
surprising, because the death patterns may overlap or in-
tegrate, providing a variety of cellular responses to vari-
ous circumstances or stimuli27.
To examine the possible protective effect of lithium on
glutamate induced damage in glioblastoma cells, we fo-
cused our investigation on two proteins, survivin and
p21WAF/Cip, because our previous study indicated that
lithium (applied in therapeutic doses of 0.5 and 2 mM) al-
tered their expression18. Survivin is a member of the
family of inhibitors of apoptosis (IAPs) proteins. How-
ever, recent studies have revealed its dual function28,29.
The cell cycle-dependent expression of survivin (increa-
sed in the G2/M phase of cell cycle) and its antiapoptotic
function led to the hypothesis that survivin connected
cell cycle with apoptosis, thus providing a death switch
for the termination of defective mitosis28,29. p21WAF/Cip, a
cell cycle regulatory molecule, is a member of cyclin–de-
pendent kinase inhibitors30. Its overexpression can re-
sult in cell cycle arrest in either G1, S or G2 phase of the
cell cycle. However, a number of recent studies have indi-
cated that p21WAF/Cip1 can assume both, anti- or pro-apop-
totic functions in response to toxic agents depending on
cell type and cellular context30.
In conclusion, the result of the present study reveals
that the treatment of glioblastoma cells with high doses
of glutamate reduces the expression of survivin. In spite
of the fact that lithium pretreatment did not alter the
survival of glutamate treated cells (if measured following
three days incubation), therapeutic dose of lithium (2
mM) induced very early alterations in survivin expres-
sion (it reverted glutamate induced suppression of sur-
vivin), suggesting that lithium may have beneficial effect
on glutamate induced cell damage in glioblastoma cells.
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U^INAK LITIJA NA GLUTAMATOM IZAZAVANA O[TE]ENJA U STANICAMA GLIOBLASTOMA
S A @ E T A K
Osim stabilizacije raspolo`enja, litij mo`e imati i neuroprotektivni u~inak. Prije smo pokazali da tretranje ljudskih
stanica glioblastoma A1235 litijem pove}ava ekspresiju proteina p21WAF/Cip1 i survivina. Cilj ovog istra`ivanja bio je
ispitati citotoksi~ni u~inak glutamata na istim stanicama, i odrediti da li litij mo`e za{tititi A1235 stanice od toksi~nog
u~inka glutamata. Citotoksi~nost glutamata odre|ivana je spektrofotometrijskom MTT metodom, a ekspresija apoptot-
skih gena Western blot metodom. Glutamat je bio izrazito toksi~an za A1235 stanice samo u koncentracijama vi{im od
100 mM. Nije izazivao apoptozu, ve} smanjivao ekspresiju survivina i pove}avao ekspresiju p21WAF/Cip1. Predtretman sa
litijem djelomi~no je dokinuo promjene u ekspresiji survivina inducirane glutamatom. U zaklju~ku, visoke koncen-
tracije glutamata toksi~ne su za stanice glioblastoma. Kod tih koncentracija predtretman stanica sa litijem (2 mM)
dokida supresiju survivina izazvanu glutamatom, {to upu}uje na zaklju~ak da bi litij mogao imati pozitivan u~inak na
glutamatom izazvana o{te}enja u stanicama glioblastoma.
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